NYS Institute for Basic Research in Developmental Disabilities Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2008
NCT00788073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

NYS institute for Basic Research in Developmental Disabilities

Active Ingredients

Drugs in Phase 2 Trials (1)

arbaclofen (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fragile X Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1